Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add filters








Year range
1.
Hepatología ; 2(1): 263-272, 2021. tab
Article in Spanish | LILACS, COLNAL | ID: biblio-1396572

ABSTRACT

El principal objetivo del tratamiento de la infección por virus de la hepatitis B es prevenir la replicación viral, con el fin de evitar las posibles complicaciones asociadas a la infección, como son las exacerbaciones o flares, las cuales pueden llegar a ser tan severas que causan una falla hepática aguda sobre crónica (ACLF). La ACLF se asocia con falla multiorgánica y una alta mortalidad, y puede ser desencadenada por la reactivación de hepatitis virales, infecciones bacterianas y consumo de alcohol, entre otros factores. Aunque la fisiopatología de la ACLF no es clara aún, parece haber una respuesta inflamatoria excesiva asociada con esta condición. El uso de análogos de nucleótidos/nucleósidos en el tratamiento de la hepatitis B crónica reduce el riesgo de morbilidad y mortalidad asociadas a la progresión de la enfermedad hepática, pero la terapia a largo plazo tiene sus limitaciones por el alto costo y por el riesgo asociado al uso indefinido. Debido a esto, en los últimos años se ha venido considerando la interrupción de la terapia en algunos pacientes por parte de las diferentes asociaciones; no obstante, aún no hay consenso en cuanto al mejor momento para hacerlo. Se describe el caso clínico de un paciente con cirrosis compensada por hepatitis B, con HBsAg positivo y HBeAg inicialmente negativo, a quien se le suspendió el tratamiento con entecavir por decisión médica, presentando una ACLF por exacerbación de la hepatitis B, con posterior deterioro y muerte del paciente. Se debe realizar una caracterización adecuada de cada paciente antes de suspender el tratamiento.


The main objective of treating hepatitis B virus infection is to prevent viral replication in order to avoid possible complications, including flares which can become so severe that can cause an acute over chronic liver failure (ACLF). ACLF is associated with multiple organ failure and high mortality, and can be triggered by reactivation of viral hepatitis, bacterial infections and alcohol consumption, among other factors. Although the pathophysiology of ACLF is not yet clear, there appears to be an excessive inflammatory response associated with this condition. The use of nucleotide/nucleoside analogs in chronic hepatitis B reduces the risk of morbidity and mortality related to the progression of the disease, but long-term treatment has its limitations due to the high cost and the risk of indefinite therapy. Due to this, in recent years the stopping of therapy in some patients has been considered by the different associations; however, there is currently no consensus as to the best time to do it. We present a clinical report of a patient with compensated hepatitis B cirrhosis, with positive HBsAg and initially negative HBeAg, who stopped treatment with entecavir by medical instruction, developing ACLF due to exacerbation of hepatitis B, with subsequent deterioration of the patient condition and ultimately death. An adequate characterization of each patient must be carried out before stopping treatment.


Subject(s)
Humans , Antiviral Agents , Liver Failure , Hepatitis B , Recurrence , Fibrosis , Hepatitis, Chronic
2.
Organ Transplantation ; (6): 82-2020.
Article in Chinese | WPRIM | ID: wpr-781859

ABSTRACT

Objective To analyze the difference and influential factors of clinical prognosis between liver transplantation with autoimmune liver disease (AILD) and viral hepatitis cirrhosis. Methods Clinical data of 75 recipients undergoing liver transplantation from January 2002 to January 2017 were retrospectively analyzed. All recipients were divided into the AILD group (n=25) and viral hepatitis cirrhosis group (n=50). The intraoperative conditions of the recipients were observed including warm ischemia time, cold ischemia time, operation time, anhepatic phase and blood transfusion volume. Postoperative complications were observed including severe acute kidney injury (AKI), infection, acute rejection, biliary tract-related complications, vascular-related complications and post transplantation diabetes mellitus (PTDM). The follow-up status were monitored after discharge. The prognostic factors of liver transplant recipients were analyzed. Results The warm ischemia time, cold ischemia time, operation time and anhepatic phase did not significantly differ between two groups (all P > 0.05). In the AILD group, the incidence of postoperative acute rejection was remarkably higher, whereas the incidence of postoperative severe AKI was significantly lower than those in the viral hepatitis cirrhosis group (both P < 0.05). The postoperative 1-, 3- and 5-year survival rates in the AILD group was 92%, 87%, and 87%, which did not significantly differ from 88%, 88% and 88% in the viral hepatitis cirrhosis group (all P > 0.05). Univariate analysis showed that age, model for end-stage liver disease (MELD) score, severe AKI, infection and biliary tract-related complications were the influencing factors of clinical prognosis of the recipients (all P < 0.05). Conclusions The overall survival prognosis does not significantly differ between the AILD and viral hepatitis cirrhosis groups. Age, MELD score, severe AKI, infection and biliary tract-related complications are the risk factors affecting the clinical prognosis of liver transplantation recipients.

3.
Malaysian Journal of Medical Sciences ; : 59-65, 2019.
Article in English | WPRIM | ID: wpr-780694

ABSTRACT

@#Background: Liver cirrhosis and the child-Turcotte-Pugh (CTP) score are inseparable entities in liver disease. CTP score is largely known as the mortality and prognosis predictor. Nevertheless, ferritin emerges as a simple biomarker related to prognosis. The study aimed to determine whether there was a significant correlation between serum ferritin levels and CTP score. Methods: The study analysed 54 decompensated liver cirrhotic patients including 17 females and 37 males between May 2016 and May 2017 at the Haji Adam Malik General Hospital, Medan, Indonesia. Ferritin levels were, then, divided into trichotomous cut-off value (< 200 ng/ mL, n = 22; 200–400 ng/mL, n = 5; and > 400 ng/mL, n = 27). Data was analysed using SPSS version 12.0 (continuous variables were assessed by the Kruskal-Wallis test and Chi-square test was used for categorical variables). In addition, Spearman correlation test was used to determine any significant correlation between ferritin levels and CTP score. Results: Based on data analysis, gender and CTP score were related to higher ferritin levels (P = 0.002 and P = 0.018, respectively). Furthermore, a significant correlation between serum ferritin levels and CTP score was obtained in to moderate degree (P = 0.000; r = 0.487). Conclusions: There might be a significant role of serum ferritin levels in predicting mortality and prognosis among decompensated liver cirrhosis patients but it still needs further attention.

4.
Chinese Journal of Experimental and Clinical Virology ; (6): 57-61, 2017.
Article in Chinese | WPRIM | ID: wpr-807983

ABSTRACT

Objective@#We aimed, in our prospective study, to assess the predictive value of serum non-invasive and biochemical markers for clinical diagnosis of significant fibrosis (including early stages).@*Methods@#We measured sH2a levels in serum, comparing with routine liver function markers. We compared blindly pretreatment serum samples from a cohort of hepatitis B patients without non-alcoholic fatty liver disease(NAFLD), which had histological grades of liver fibrosis, with NAFLD individuals and CHB with NAFLD patients. Statistical analysis was by Student′s t test, and receiver-operating characteristic (ROC) curves were drawn.@*Results@#ROC curves showed that serum sH2a had greater diagnostic performance than routine liver function markers compared with histological grades of liver fibrosis(S0, S1-2, S3-4). ROC curves showed that using a sH2a cut-off point of 0.79 was with highest sensitivity as 63% and highest specificity as 80%. And sensitivity as 96.7% and specificity as 75.5% when using a sH2a cut-off point of 0.77.@*Conclusions@#sH2a has the potential to be a uniquely sensitive and specific novel marker for liver fibrosis and function.

5.
Chinese Journal of Clinical Laboratory Science ; (12)2006.
Article in Chinese | WPRIM | ID: wpr-593117

ABSTRACT

Objective To investigate the levels of platelet-derived growth factor-BB (PDGF-BB) and its role in the pathogenesis of the patients with hepatic diseases.Methods The levels of serum PDGF-BB in 30 chronic patients (hepatitis B,26; hepatitis C,4),24 patients with post-hepatitis cirrhosis,30 patients with primary hepatocellular carcinoma,and 20 normal controls were measured by ELISA.The levels of PDGF-B mRNA in peripheral blood mononuclear cells were measured by reverse transcription polymerase chain reaction (RT-PCR).Results The serum levels of PDGF-BB and the levels of PDGF-B mRNA in peripheral blood mononuclear cells were significantly higher in the patients with hepatic diseases (F=1774.40,1037.42,P

6.
China Journal of Traditional Chinese Medicine and Pharmacy ; (12)2005.
Article in Chinese | WPRIM | ID: wpr-567184

ABSTRACT

Objective:To investigate the efficacy and security of umbilical Chinese materia medica paste on the endotoxemia of cirrhosis patients.Methods:Based on the TAL blood cell matrix color test,80 cases of cirrhosis patients with endotoxemia positive were divided into two groups by randomly number:40 in the received regular treatment period for both groups was one month.The clinical symptoms was given to the level of treatments;Additionally,Chinese materia medica paste on umbilicus was given to the treatment group,the endotoxin,ammonia and complement component 3 in serum,cruor function,liver function,and blood routine test were statistical analysised and efficacy compared in both groups after treatment.Results:After treatment,endotoxin decreased significantly in the treatment group and the control group(P

SELECTION OF CITATIONS
SEARCH DETAIL